Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico has maintained an Outperform rating on Dianthus Therapeutics (NASDAQ:DNTH) and increased the price target from $23 to $24.
January 26, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains an Outperform rating on Dianthus Therapeutics and raises the price target from $23 to $24.
The increase in price target by a reputable analyst suggests a positive outlook on the company's performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100